KH607 Meets Primary Endpoint in Phase 2b Trial for Major Depressive Disorder
核心洞察
Kanghong Pharmaceutical (搜索) and Vanotech announced successful completion of a Phase 2b clinical trial for KH607 in adults with major depressive disorder (搜索), meeting the primary endpoint with strong efficacy results.
The investigational GABA receptor (搜索) positive allosteric modulator demonstrated rapid, robust, and sustained antidepressant effects with a favorable safety profile and no serious safety concerns.
Based on these positive outcomes, the companies plan to advance KH607 into Phase 3 development, marking an important milestone for this novel treatment approach targeting mood regulation.
Kanghong Pharmaceutical (搜索) and Vanotech Ltd (搜索). announced the successful completion of a Phase 2b clinical trial evaluating KH607 in adults with major depressive disorder (搜索) (MDD (搜索)), with the study meeting its primary endpoint and demonstrating strong efficacy alongside a favorable safety profile.
Trial Results and Efficacy Profile
The Phase 2b study demonstrated that KH607 exhibited rapid, robust, and sustained antidepressant effects, reinforcing its potential as a promising new treatment option for patients with MDD (搜索). The investigational therapy was generally well tolerated throughout the trial period, with no serious safety concerns identified during the study.
"These results mark an important milestone for KH607 and provide strong validation of its therapeutic potential in MDD (搜索)," said Avner Ingerman, MD, President and Chief Medical Officer of Vanotech, Ltd. "We are encouraged by the combination of efficacy and tolerability observed in this study."
Drug Mechanism and Development Strategy
KH607 is an investigational oral small molecule and positive allosteric modulator (PAM) of the GABA receptor (搜索). The compound is designed to selectively target receptor subtypes implicated in mood regulation and is being developed for the treatment of major depressive disorder (搜索) and other neuropsychiatric conditions.
The overall safety profile observed in the Phase 2b trial supports continued clinical development and advancement into later-stage studies. Based on these positive outcomes, the companies plan to advance KH607 into Phase 3 development.
Addressing Unmet Medical Need
Major depressive disorder (搜索) represents a significant global health challenge, affecting more than 280 million people worldwide. The condition is characterized by persistent low mood, loss of interest, and a range of cognitive and physical symptoms that impair daily functioning. Despite available therapies, many patients fail to achieve adequate response or remission, underscoring the need for new treatment options.
Company Profiles
Kanghong Pharmaceutical (搜索) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies addressing unmet medical needs. The company maintains a diversified pipeline across multiple therapeutic areas, supported by integrated research, development, and manufacturing capabilities.
Vanotech Ltd (搜索). is a clinical-stage biopharmaceutical company responsible for the global clinical development of KH607 and other pipeline assets. Headquartered in Rockaway, New Jersey, Vanotech collaborates with partners to advance novel therapies for central nervous system and other disorders.